Is Regeneron Pharmaceuticals, Inc. (REGN) Overvalued?
We dive into why Regeneron Pharmaceuticals, Inc. (REGN) could be considered overvalued on 2026-07-15, based on AAII’s Value Score and Grade.Michael Rose
Stock Evaluator: Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals, Inc. REGN
$762.63
24.29
3.29%
July 31, 2026 4:00:00 PM
EST
Volume: 1,158,212
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Commentary & Analysis
Which Is a Better Investment, Amgen Inc. or Regeneron Pharmaceuticals, Inc. Stock?
Learn more about whether Amgen Inc. or Regeneron Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Why Regeneron Pharmaceuticals, Inc.’s (REGN) Stock Is Down 10.63%
As of Monday, May 18, Regeneron Pharmaceuticals, Inc.’s REGN share price has dipped by 10.63%, which has investors questioning if this is right time to buy.Michael Rose
Why Regeneron Pharmaceuticals, Inc.’s (REGN) Stock Is Down 6.45%
As of Wednesday, April 29, Regeneron Pharmaceuticals, Inc.’s REGN share price has dipped by 6.45%, which has investors questioning if this is right time to buy.Michael Rose
What You Need to Know About Regeneron Pharmaceuticals, Inc.'s Q2 Earnings
Regeneron Pharmaceuticals, Inc.'s fiscal Q2 earnings report was released on Wednesday, April 29. Let's dive in to see if (REGN) missed or beat analyst's expectations.Michael Rose
Financial Summary
| Share Statistics | REGN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $76,152.4 | $252.6 | 95% |
|
| Shares Out (Mil) | 106.0 | 52.3 | 63% |
|
| Institutional Ownership | 96.0% | 92.1% | 69% |
|
| Float (Mil) | 97.7 | 40.2 | 61% |
|
| Beta | 0.24 | 0.95 | 14% |
|
| Avg Daily Volume (000s) | 906 | 455 | 69% |
|
| Price Change (52-week) |
37.5% | 52.9% | 73% |
|
| Growth | REGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 11.0% | 13.6% | 62% |
|
| Net Income (5yr) | 5.1% | (9.9%) | 47% |
|
| EPS (5yr) | 6.3% | 16.0% | 40 |
|
| Dividends (5yr) | 0.0% | 0.0% | 96% |
|
| Cash Flow (5yr) | 2.5% | (15.6%) | 66% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 17 | 28 | 27 | |
| Current EPS | $15.967 | $52.024 | $59.167 | |
| Month Ago EPS | $13.075 | $46.212 | $53.768 | |
| # Rev Up | 0 | 4 | 0 | |
| # Rev Down | 2 | 0 | 1 | |
| Three Months Ago EPS | $13.001 | $46.372 | $53.821 | |
| Year/Year Chg | 30.6% | 25.4% | 59.8% | |
| Financials | REGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $15,535 | $38 | 89% |
|
| Net Income (TTM) (Mil) | $4,329 | ($43) | 96% |
|
| EPS (TTM) | $41.884 | ($1.600) | 99% |
|
| Operating Cash Flow (TTM) (Mil) | $4,681 | ($31) | 95% |
|
| Net Cash Flow (TTM) (Mil) | $450 | $5 | 90% |
|
| Long-Term Debt (Q1) (Mil) | $1,987 | $5 | 74% |
|
| Enterprise Value (Q1) (Mil) | $58,611 | $180 | 93% |
|
| Valuation | REGN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.41 | 2.56 | 58% |
|
| P/E | 18.9 | 19.0 | 47% |
|
| Dividend Yield | 0.5% | 0.0% | 62% |
|
| PEG (5yr hist) | 3.0 | 0.9 | 78% |
|
| Ratios | REGN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 44.5% | 63.8% | 56% |
|
| Net Margin | 27.9% | (67.3%) | 87% |
|
| ROA | 10.8% | (49.8%) | 88% |
|
| ROE | 14.0% | (55.5%) | 69% |
|
| Liabilities to Assets | 24.0% | 30.3% | 16% |
|
| F-Score | 5 | 3 | 51% |
|
Regeneron Pharmaceuticals, Inc. did not pass any screens on 7/31/2026.
